USFDA approves Glenmarks Prochlorperazine Maleate Tablets, Health News, ET HealthWorld
Exclusive
USFDA approves Glenmarks Prochlorperazine Maleate Tablets
Glenmarks Prochlorperazine Maleate Tablets, 5 mg and 10 mg the generic version of Compazine tablets, received final approval from USFDA
March 20, 2023, 10:45 IST
Mumbai: Glenmark Pharmaceuticals has received final approval by the United States Food and Drug Administration (
USFDA
) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the generic version of Compazine tablets, 5 mg and 10 mg, of GlaxoSmithKline. Prochlorperazine Maleate tablets will be distributed in the US by Glenmark.
The Compazine tablets, 5 mg and 10 mg market had achieved annual sales of approximately $26.9 million, as per the IQVIATM sales data for the 12-month period ending January 2023.
As per Glenmarks current portfolio, 182 products are authorized for distribution in the U.S. marketplace, and 46 ANDAs pending approval with the USFDA.
Follow and connect with us on Twitter, Facebook, Linkedin,
Monday, March 20, 2023 at 5:15 am